Innate Pharma S.A. (LON:0EVI)
United Kingdom · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 102.89M -16.7% |
| Revenue (ttm) | 8.45M -22.4% |
| Net Income | -40.86M |
| EPS | -0.43 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 30.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,215 |
| Open | 1.294 |
| Previous Close | 1.310 |
| Day's Range | 1.286 - 1.320 |
| 52-Week Range | 1.040 - 2.330 |
| Beta | 1.22 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking ant... [Read more]
Financial Performance
In 2025, Innate Pharma's revenue was 9.01 million, a decrease of -55.25% compared to the previous year's 20.12 million. Losses were -49.18 million, -0.59% less than in 2024.
Financial numbers in EUR Financial StatementsNews
Innate Pharma Transcript: Stifel 2026 Healthcare Conference 2026
IPH4502 dose-finding results are due the week of Nov. 18, 2026, while lacutamab’s TELLOMAK-3 trial is expected to start in Q1 2027. Accelerated approval is targeted for H1 2028; PACIFIC-9 results are expected in H1 2027.
Innate Pharma Q3 Earnings Call Highlights
Innate Pharma NASDAQ: IPHA said it has initiated a Phase 3 study of its lymphoma drug lacutamab and expects to present Phase 1 data for its experimental cancer treatment IPH4502 on Nov. 18, as the com...
Innate Pharma Earnings Call Transcript: Q3 2026
The portfolio advanced with TELLOMAK-3 initiation, an effective $75 million Sobi upfront payment, and €96.8 million in cash supporting a runway through Q1 2028. IPH4502 data are due in November 2026 and PACIFIC-9 results are expected in H1 2027.
Innate Pharma Earnings release: Q3 2026
Innate Pharma released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Innate Pharma Earnings release: Q3 2026
Innate Pharma released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Innate Pharma Slides: Q3 2026
Innate Pharma has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Innate Pharma Reports Third Quarter 2026 Business and Financial Update
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its financial update for the nine mon...
Innate Pharma Slides: Corporate presentation
Innate Pharma has posted slides in relation to its latest quarterly earnings report, which was published on October 28, 2026.
Innate Pharma S.A. Announces PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027
Innate Pharma S.A. announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously...
Innate Pharma announces AstraZeneca updated timing for PACIFIC-9 data readout
Innate Pharma (IPHA) announced that AstraZeneca (AZN) has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second…
Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca has updated the exp...
Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference
MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference.
Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update
MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma announces conference call for third quarter 2026 business and financial update.
Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround
Innate Pharma (IPHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revi...
Innate Pharma Q2 Earnings Call Highlights
Innate Pharma NASDAQ: IPHA said its first-half 2026 developments included the closing of a strategic partnership with Sobi for lacutamab, completion of dose-escalation enrollment for IPH4502, and comp...
Innate Pharma Earnings Call Transcript: Q2 2026
Strategic partnerships and financing have strengthened the balance sheet, enabling advancement of key programs including lacutamab, IPH4502, and monalizumab. Multiple clinical catalysts are expected in H2 2026, with cash runway projected through Q1 2028.
Innate Pharma Earnings release: Q2 2026
Innate Pharma released its Q2 2026 earnings on September 17, 2026, summarizing the period's financial results.
Innate Pharma Earnings release: Q2 2026
Innate Pharma released its Q2 2026 earnings on September 17, 2026, summarizing the period's financial results.
Innate Pharma Quarterly report: Q2 2026
Innate Pharma has published its Q2 2026 quarterly earnings report on September 17, 2026.
Innate Pharma Slides: Q2 2026
Innate Pharma has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on September 17, 2026.
Innate Pharma Slides: Corporate presentation
Innate Pharma has posted slides in relation to its latest quarterly earnings report, which was published on September 17, 2026.
Innate Pharma Reports First Half 2026 Business Update and Financial Results
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results fo...
Innate Pharma says previously announced partnership with Sobi now effective
Innate Pharma (IPHA) “announced that the previously announced strategic partnership with Sobi is now effective following the expiration of applicable antitrust waiting periods and completion of other ...
Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the previously announced strate...
Innate Pharma Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The discussion highlighted a strategic focus on three core assets, with key partnerships supporting late-stage development and commercialization. Upcoming data from IPH4502 and PACIFIC-9 are major catalysts, while innovative ADC approaches and regulatory milestones are expected to drive future growth.